Weihao Xu
Founder & Chief Executive Officer Kali Therapeutics
Seminars
Thursday 10th September 2026
What can be Improved Upon for Existing Drugs?
8:45 am
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
